“…6,7,[34][35][36][37] In our study, poor staff knowledge of isoniazid preventive therapy and poor compliance with guidelines were found to be barriers to the initiation of therapy. Similar barriers have been reported in other countries: in India, health-care workers reported that unclear guidelines on child contact management inhibited their ability to implement therapy; 38 in Thailand, doctors were reluctant to initiate therapy due to concerns about isoniazid toxicity and resistance; 22 in Australia, doctors actively advised patients not to use isoniazid preventive therapy; 34 in the United States of America, medical graduates did not believe isoniazid preventive therapy was protective against disease progression; 39 and, in Malawi, health-care workers felt that screening child contacts by chest radiography was not worthwhile. 33 As in other countries, we found that primary caregivers' acceptance of the child contact management programme was hindered by barriers such as limited knowledge of isoniazid preventive therapy, difficulty accessing screening and treatment and reluctance to treat asymptomatic children.…”